Compugen, Merck Serono form startup biomarker company; Did Amylin lie about 'concealed' Byetta study?;

 @FierceBiotech: : Immunotherapies make a comeback at Big | Follow @FierceBiotech

 @JohnCFierce: Lexicon boasts of positive results in PhIIb diabetes study--(trying to steer clear of the safety concerns related to SGLT2s). Story | Follow @JohnCFierce

 @RyanMFierce: FierceBiotech IT lands in Philly for DIA summit. Let me know how we're doing. More | Follow @RyanMFierce

> Compugen has found a new use for its computational discovery technologies. The Tel Aviv, Israel-based company ($CGEN) and global drugmaker Merck Serono have joined forces to form a startup called Neviah Genomics, which will focus on developing diagnostic tests to spot drug-induced toxicities, which cause drugs to fail in clinical trials. Report

> AMAG ($AMAG) won a $15 million milestone from Takeda following the European approval of ferumoxytol, an IV therapy for iron deficiency anemia. Story

> TheStreet's Adam Feuerstein reports this morning that Amylin ($AMLN) "concealed" a study from regulators that raised safety concerns on Byetta. And he says the records show that Amylin execs lied to investors by failing to reveal to them that the hidden study played a role in the FDA's rejection of Bydureon. Story

> AbGenomics International says it has raised $11 million in a current financing round designed to fuel development of its antibody candidates for cancer and autoimmune diseases. Release

> Shire's ($SHPGY) Adderall XR just took a torpedo to the keel. U.S. regulators have approved the first third-party rival to the big-selling ADHD drug. The agency thus ushers onto the market a lower-priced rival from Actavis ($ACT) more than a year earlier than expected. Story

> Rensellaer Polytechnic has opened a $2.45 million stem cell lab. Report

Pharma News

 @FiercePharma: Andrew Witty's letter to EU urges reference pricing, parallel trade changes to keep meds flowing to Greece, et al. Report | Follow @FiercePharma

> FDA hits Shire with early nod for Adderall XR copycat. Story

> Xarelto, Pradaxa find reprieve in Eliquis delay. Article

> Teva's patent victory on Copaxone boosts franchise long-term. More

Medical Device News

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: Yet another reason why device and Dx companies are turning to China. Item | Follow @MarkHFierce

 @DamianFierce: Teleflex dropped $30M on an MIT spin-out for its safety-boosting device coating. Story | Follow @DamianFierce

> DSM closes $360M deal for Kensey Nash. More

> Arstasis draws $38M in new financing. Story

> St. Jude blames Durata lead failure on 'external abrasion'. Article

Biotech IT News

> Why Microsoft's Yammer buyout matters in pharma. Article

> Merck Serono, Compugen form startup to catch drug toxicity early. More

> Oracle rolls out cloud apps for clinical trial recruitment. Story

> Bay Area startup delivers clinical trials analytics from the cloud. News

And Finally… Researchers say that the appetite-inducing hormone ghrelin is responsible for making people want to eat, even when they are full. Release

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.